Unit of Obstetrics and Gynecology, Department of Medical and Surgical Sciences, University "Magna Græcia" of Catanzaro, Viale Europa, 88100, Catanzaro, Italy.
Consultant in Obstetrics and Foetal Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Arch Gynecol Obstet. 2021 May;303(5):1185-1190. doi: 10.1007/s00404-020-05846-2. Epub 2020 Oct 27.
Nowadays several Prenatal Tests for Chromosomal Abnormalities Detection (PTCAD) are available. In those cases in which there is not an Institutional protocol to advise women about the available PTCAD, the choice of which one to undergo is up to the woman and largely depends on her knowledge about them. Therefore, we decided to evaluate, as a primary outcome, knowledge about PTCAD among pregnant women attending our Term Clinic. As a secondary outcome we evaluated the relationship between the patient's knowledge and the subsequently chosen PTCAD.
From August 2017 to August 2018 an anonymous questionnaire with multiple-choice answers was administered to all pregnant women attending our Term antenatal Clinic, a tertiary obstetric unit in Catanzaro (Italy).
Three hundred and twenty-five pregnant women were enrolled in the study. We observed that 28.8% of the pregnant women that chose one of the PTCAD, avoided the first trimester combined screening test; among these, 11.4% were in favour of the cell-free foetal DNA test. The latter was erroneously considered diagnostic by 34.3% of the women that had chosen it.
This study demonstrated that women's knowledge about PTCAD is poor and that there is a potentially dangerous confusion between the words 'screening' and 'diagnostic'. Informative campaigns about PTCAD and the application of dedicated antenatal counselling appointments should be a health-care priority to avoid unnecessary risks and costs for pregnant women and possible legal issues.
如今有多种用于检测染色体异常的产前检测（Prenatal Test for Chromosomal Abnormalities Detection，PTCAD）可供选择。在没有机构协议向女性提供可用的 PTCAD 咨询的情况下，选择进行哪种检测取决于女性自身，并且在很大程度上取决于她们对这些检测的了解。因此，我们决定将参加我们足月门诊的孕妇对 PTCAD 的了解程度作为主要结果进行评估。作为次要结果，我们评估了患者知识与随后选择的 PTCAD 之间的关系。
从 2017 年 8 月至 2018 年 8 月，我们向所有参加我们足月产前门诊的孕妇发放了一份匿名多项选择题问卷，该门诊是意大利卡坦扎罗的一家三级产科单位。
共有 325 名孕妇参加了这项研究。我们观察到，选择进行一种 PTCAD 的孕妇中有 28.8%避免了早孕期联合筛查试验；其中，11.4%的孕妇支持游离胎儿 DNA 检测。选择该检测的孕妇中有 34.3%错误地认为它是诊断性的。
本研究表明，孕妇对 PTCAD 的了解程度较差，并且在“筛查”和“诊断”这两个词之间存在潜在的混淆。关于 PTCAD 的宣传活动和应用专门的产前咨询预约应该成为医疗保健的重点，以避免对孕妇造成不必要的风险和费用，并避免可能出现的法律问题。
